ArticleClinical pharmacology and therapeutics2025
Combined Biologics and Exclusive Enteral Nutrition Promote Early Transmural Healing and Improve Long-Term Outcomes in Crohn's Disease: A Multicenter Retrospective Study.
Article in Clinical pharmacology and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Exclusive enteral nutrition for induction of remission in Crohn's disease in adults: A systematic review and meta-analysis of randomized trials and real-world studies.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transmural healing (TH), a comprehensive therapeutic target in Crohn's disease (CD), is associated with reduced long-term complications. However, evidence on the role of exclusive enteral nutrition (EEN) in TH remains limited. This study aimed to evaluate the efficacy of biologics combined with 16-week EEN in achieving early TH and improving clinical outcomes. This real-world, multicenter retrospective study analyzed medical records of patients with moderate-to-severe CD from 2016 to 2024. Patients received either biologics with concomitant 16-week EEN (BioEEN) or biologics alone (Bio). Clinical and endoscopic outcomes, including transmural healing, were assessed at week 16, year 1, and year 2. At baseline, demographic and clinical characteristics were comparable between the two groups. The BioEEN group demonstrated superior clinical response rates compared to the Bio group (95.1% vs. 70.6% at week 16; P < 0.001), with sustained benefits at week 52 (87.8% vs. 59.5%; P < 0.001). Subgroup analysis revealed higher endoscopic response, mucosal healing, and TH rates in both colorectal and ileal segments at weeks 16 and 52 in the BioEEN group. Additionally, the BioEEN group had significantly lower rates of surgery, escalated treatment, bowel damage progression, and disease relapse at 1 and 2 years. Regression analysis identified the 16-week EEN as the sole protective factor for early transmural healing and improved long-term outcomes. Combined treatment of biologics and 16-week EEN promotes early transmural healing, thereby enhancing long-term clinical outcomes in CD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.